Edition:
United Kingdom

Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

15.98USD
16 Feb 2018
Change (% chg)

$0.42 (+2.70%)
Prev Close
$15.56
Open
$15.52
Day's High
$16.32
Day's Low
$15.52
Volume
476,625
Avg. Vol
641,446
52-wk High
$25.92
52-wk Low
$8.15

Chart for

About

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $2,309.91
Shares Outstanding(Mil.): 113.40
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application

* CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING THAT TEVA PHARMACEUTICALS USA SUBMITTED AN ABBREVIATED NEW DRUG APPLICATION TO FDA

05 Feb 2018

BRIEF-Corcept Therapeutics, Dohmen Entered Into Settlement Agreement And Mutual Release Of Any And All Claims That May Have Existed Between Parties

* CORCEPT THERAPEUTICS - CO, DOHMEN ENTERED INTO SETTLEMENT AGREEMENT AND MUTUAL RELEASE OF ANY AND ALL CLAIMS THAT MAY HAVE EXISTED BETWEEN PARTIES

17 Jan 2018

BRIEF-Corcept Therapeutics posts Q3 earnings per share $0.11

* Corcept Therapeutics announces third quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update

02 Nov 2017

BRIEF-Corcept Therapeutic says Dohmen Life Science Services filed a complaint alleging Corcept unlawfully terminated Dohmen agreement

* Corcept Therapeutics Inc - On August 7, 2017, Dohmen Life Science Services filed a complaint alleging corcept unlawfully terminated dohmen agreement

30 Aug 2017

Competitors

Earnings vs. Estimates